31 October 2019 | With the PGXperts™ software platform from HMG Systems Engineering (HMG), physicians are now able to consider pharmacogenetic risks as well as interactions between drugs, foods and beverages for the first time ever, when prescribing medication. Fast, precise and safe! HMG will be presenting its innovative solutions for a paradigm shift in medicine at the joint Bayern Innovativ stand in hall 3 E83 as part of the world’s largest medical trade fair MEDICA in Düsseldorf.

As each individual person metabolises drugs differently, during medication, doctors are regularly confronted with adverse drug reactions or therapy failure. It is known that undesired side effects can arise from the simultaneous intake of several drugs as well as from foods and beverages. This risk increases exponentially with the number of active substances. What is completely new is the approach to consider the risks which have their origin in the individual genetic characteristics, which also have an impact on the desired effectiveness and tolerability of medicine. The holistic consideration of these interaction risks enables a personalised medication together with more safety for the patient.

Drug therapy safety has become more and more important over the past few years. One out of five Germans and more than 40 % of all persons over the age of 65, permanently take five or more different drugs. Scientific studies in recent years have shown that about 7% of all hospitalisations and approximately 3-5% of all mortalities are caused by adverse drug effects.

Three steps to personalised medication with PGXperts™

For personalised medication in daily practice, HMG offers a simple approach to risk stratification in drug therapy.

In the first step, doctors can check the medication and identify interaction risks within seconds via a web-based application in their practice or a mobile application during home visits. The physicians also immediately recognise pharmacogenetic interaction risks and can decide whether a genetic test is necessary or recommendable before prescribing a medication.

In this case, the second step is a pharmacogenetic examination with the aim of determining individual genetic characteristics. For this purpose, HMG cooperates with the Institute of Human Genetics at the University Hospital Bonn. The results and interpretation of the molecular genetic examination are sent to the attending physician in a report within one week.

In the third step, this report serves as a detailed basis of decision-making and assists the physician in optimising the current medication. In addition, the patient receives his personal pharmacogenetic profile. The profile contains an overview of the individual genetic variations and gives indications of critical active substances in any future diseases of the patient.

PGXperts™ solutions seamlessly integrate with an existing hospital/practice IT infrastructure to address pharmacological and pharmacogenetic interaction risks in the medical decision-making process.

From 18th to 21st of November 2019 we will be exhibiting at the leading international medical technology trade fair MEDICA in Düsseldorf, Germany. Visit us at Hall 3/ E83 to learn more about our solutions for personalised medication in the clinical practice.

Are you interested in a personal consultation or a product presentation? Contact us at: info@munoz-galeano.com. We look forward to your visit!